We actively develop, acquire, and market wound care products that exhibit innovative technologies, empower caregivers, and focus on the unmet needs of patients.  As the science underlying the issues of chronic wounds advances, our goal is to be a leader in the development of active therapies.

Three significant new advanced wound care products offer unique therapeutic opportunities: MEDIHONEY™, ALGICELL™ Ag, and the MOBILITY1™ device.

MEDIHONEY™ Active Leptospermum Honey dressings: 
MEDIHONEY™ is the first honey-based product cleared for use by Health Canada and also the first cleared for use by the FDA.  These unique dressings contain Active Leptospermum Honey. The dressings can be used in all phases of wound healing and could be considered a key dressing in any wound bed preparation protocol.  These qualities can help to take much of the guesswork out of wound management.

ALGICELL™ Ag antimicrobial silver alginate dressing:
ALGICELL™ delivers 1.4% ionic silver at a slow consistent release rate for strong broad-spectrum efficacy, has an optimal gelling profile, and superior absorption.  Priced in-line with current reimbursement codes, caregivers can reach for this best-in-class dressing more often than other antimicrobial silver dressings, and achieve optimal economic and clinical outcomes. 

MOBILITY1™ Intermittent Pneumatic Compression Device: 
MOBILITY1 is the only intermittent pneumatic compression device that allows mobility for patients who suffer from various disorder such as lymphedema or chronic venous insufficiency and want to continue to work,  go on vacation, or simply live their normal daily life while receiving optimal therapy.

We also provide a full line of standard advanced wound care dressings, traditional wound care dressings, burn care dressings, skin care & patient bathing products, and specialty securement & closure devices.